Hard-to-treat Myc-driven cancers may be susceptible to drug already used in clinic
Friday, December 14, 2012 - 11:00
in Health & Medicine
Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study.